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Abstract: In recent studies, evidence has been
provided for complement activation early during
the onset of experimental sepsis. Excessive pro-
duction of the anaphylatoxin C5a thereby appears
to elicit various harmful effects. Blockade of C5a
or C5a receptor (C5aR) at the start of experimen-
tal sepsis has been demonstrated to greatly im-
prove survival in rodents. There is evidence that
C5a, during the onset of sepsis, enhances the pro-
duction of various proinflammatory mediators in
different cell types. Besides its known, other proin-
flammatory effects, recent work suggested an in-
hibitory role of C5a for innate-immune functions
of phagocytic cells (phagocytosis, reactive oxygen
species production, chemotaxis) during experi-
mental sepsis. This review article provides an over-
view of the important role of C5a/C5aR activation
for the onset and development of sepsis. J. Leukoc.
Biol. 74: 966–970; 2003.
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INTRODUCTION
The complement system represents a powerful key player of
humoral defense against invading microorganisms. The com-
plement system uses a variety of serum proteins, which interact
in a cascade of activation steps. The ultimate, direct function of
complement activation in the context of humoral defense is
production of mediators that are proinflammatory and promote
the phagocytosis as well as the formation of pores in the
bacteria leading to their lysis. This goal can be reached by
different pathways of complement activation, depending on the
type of trigger of activation.
The classical pathway is activated by antigen-antibody com-
plexes and requires all nine complement proteins. The lectin
pathway of complement activation is initiated by bacterial
surface sugars (mannose) via the mannose-binding lectin
(MBL) protein in serum and subsequent interaction with MBL-
activated serine proteases. Thereafter, this pathway functions
identically to the classical pathway, using C2 and C4 for
following cleavage of C3. The alternative complement pathway
is activated by bacterial lipopolysaccharide (LPS) and by re-
lated products. All complement activation pathways converge
at the level of C3 and lead to the cleavage products, C3a and
C5a, as well as the terminal membrane attack complex, C5b-9,
which forms pores in the membrane of bacteria and cells,
ultimately causing their lysis. Despite this beneficial effect of
complement activation for the humoral defense, the recent
works have underscored a variety of harmful effects associated
with activation of the complement system.
On top of the list of potentially harmful mediators is the
complement anaphylatoxin C5a. This 74 amino acid-con-
taining protein was originally found to have strong chemo-
tactic effects on neutrophils [1]. Many proinflammatory ef-
fects were discovered, such as release of granular enzymes
from phagocytic cells [2], production by neutrophils of su-
peroxide anion [3], vasodilatation together with increased
vascular permeability [4], and induction of thymocyte apo-
ptosis during sepsis [5, 6].
The corresponding seven transmembrane-spanning, G-pro-
tein-coupled receptor C5aR was cloned in 1991 [7] and has
since been discovered to play an important role for a variety of
inflammatory diseases such as the reverse-passive arthus re-
action [8] and ischemia reperfusion [9]. The complexity of
C5a/C5aR-induced effects on different immune functions and
systems is reflected by the fact that blockade of C5a or C5aR
has been suggested to be beneficial in a variety of inflammatory
disorders. Recently, blockade of C5a was demonstrated to be
beneficial in cecal ligation and puncture (CLP)-induced
polymicrobial sepsis [10]. Since then, there has been accumu-
lating evidence for a key role of C5a/C5aR activation for the
development and during the onset of sepsis. This key role of
C5a/C5aR activation will be the focus of this manuscript.
EVIDENCE FOR IMPORTANCE OF C5a
DURING SEPSIS
Earlier studies have suggested that complement activation
during human sepsis, especially as reflected in elevated levels
of C5a, is associated with significantly reduced survival rates
together with multi-organ failure when compared with less-
severe septic patients and survivors [11–13]. Experimental
studies in monkeys suggested that blockade of C5a by anti-
bodies could significantly attenuate Escherichia coli-induced
septic shock and adult respiratory distress syndrome [14, 15],
and studies in rats suggested that LPS-induced septic shock
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could be mimicked by injection of C5a, and blockade of C5a
via antibody attenuated LPS-induced responses [16].
Blockade of C5a during experimental sepsis (CLP) was
recently found to be protective in rats [10]. In this study,
antibodies to C5a were administered at the start of CLP and
showed significant improvement in terms of survival of
septic rats. Follow-up studies aimed to determine the effi-
cacy of blocking different regions of C5a by antibodies
revealed that blockade of the middle or C-terminal region of
C5a was an effective strategy in terms of improving survival
in CLP rats [17]. Also, it was demonstrated that delayed
infusion (6 and 12 h after CLP) of antibodies to C5a still
resulted in significant survival benefits for the animals. C5a
blockade during sepsis also greatly reduced appearance of
multi-organ failure in rats [18].
Besides the activation of complement in the plasma during
sepsis or after LPS infusion, recent work demonstrated that
certain cells (e.g., alveolar macrophages) and neutrophils,
when activated, are capable of cleaving C5 to generate C5a,
suggesting that C5a generation in compartments such as the
lung could be regulated independent of complement proteins
that form C5 convertases (C5-cleaving activities) [19].
C5aR IN SEPSIS
Soon after the findings in sepsis, which demonstrated benefits
of blockade of C5a with antibodies, C5aR became one focus of
interest. Blockade of C5aR by a small cyclic C5aR antagonist
as well as by antibodies to the N-terminal end of C5aR resulted
in significantly improved survival in CLP mice [5, 20]. C5aR
was originally believed to be present only in myeloid cells, but
it has since been found to be present in a broad variety of cell
types such as alveolar and bronchiolar epithelial cells [21, 22]
and endothelial cells [23–25]. It is interesting that a strong
increase in C5aR surface expression was found early (6 h) after
CLP in mouse lung, liver, kidney, and heart [5]. This increase
was found to be strongly dependent on plasma interleukin
(IL)-6, as IL-6 blockade in CLP mice inhibited the C5aR
increase in all four organs and resulted in improved survival in
a dose-dependent manner [26]. C5aR blockade with antibod-
ies, in turn, resulted in decreased IL-6 plasma levels at 6 h
after sepsis [5]. These data suggest a complex interaction and
positive feedback between IL-6 generation and C5aR up-
regulation and between C5aR activation (via C5a) and IL-6
production. As C5a is believed to be activated within the first
few hours of CLP-induced sepsis in rodents (and IL-6 levels
are peaking at 6 h), it is tempting to hypothesize that the
early C5a generation may be the driving force for up-regulation
of IL-6. Earlier findings in alveolar epithelial cells demon-
strated that LPS-induced generation of mediators, such as
tumor necrosis factor  (TNF-) and chemokines (macrophage-
inflammatory protein-2, cytokine-induced neutrophil chemoat-
tractant), were strongly enhanced in the copresence of C5a. In
vitro data from our group indicate that C5a may also enhance
LPS-induced IL-6 production in granulocytes [27]. The same
has been suggested for peripheral blood mononuclear cells
(PBMC) [28]. In such a scenario, early C5a generation during
sepsis would boost mediator-induced production of IL-6 in the
serum, resulting in fast up-regulation of C5aR in various
organs, which in turn, could make these organs more suscep-
tible to C5a effects but also result in reducing circulating C5a
levels by binding and internalizing C5a as a potential negative
feedback (Fig. 1). Increased C5aR gene expression was also
found during various human kidney diseases [29]. The effect,
however, of C5aR increase and activation in the various organs
is unclear so far.
In contrast to organs, there is evidence that C5aR expression
in neutrophils may be regulated differently during sepsis, as
binding of radiolabeled C5a to PMN has been demonstrated to
be vastly down-regulated during CLP-induced sepsis in ro-
dents [18], which was reversed by blockade of C5a with anti-
bodies. The loss of C5aR on blood neutrophils appears to be a
result of internalization of C5aR–C5a complexes (R-F. Guo,
N. C. Riedemann et al., submitted). An earlier study suggested
similar findings in a model of LPS infusion in rabbits [30].
Recently, in humans with sepsis, C5aR expression on granu-
locytes was also described to be down-regulated [31]. Data
from our group suggest that C5aR expression in PMN during
experimental sepsis may be an indicator for outcome and
therefore, may have potential for prognostic use in the clinic
(R-F. Guo, N. C. Riedemann et al., submitted).
C5a EFFECTS ON CYTOKINE PRODUCTION
IN VITRO
In vitro results with C5a stimulation of various cell types did
not result in significant mediator generation in most cases. As
mentioned earlier, when alveolar epithelial cells were costimu-
lated with LPS and C5a, a much higher production of TNF-
and chemokines could be observed when compared with cells
stimulated only with LPS [32], suggesting a strong, stimulatory
role of C5a for the mediator-induced production of various
proinflammatory cytokines. Earlier studies in PBMC had dem-
onstrated that C5a stimulation resulted in gene transcription
(but not translation) for IL-1, as significant increases in
protein expression for IL-1 could not be detected [33, 34].
Another study demonstrated that prestimulation of granulo-
cytes with C5a or other chemoattractants resulted in signifi-
cantly reduced LPS-induced IL-8 production, and costimula-
tion with C5a and LPS resulted in a synergistic increase of IL-8
production as compared with LPS-only-stimulated granulo-
cytes [35]. In the case of LPS-induced production of the
proinflammatory cytokine IL-6 by PBMC, similar findings have
been made when they were costimulated with C5a and LPS
[28]. Recent findings of our group suggest that this could be
true in granulocytes as well and may have systemic implica-
tions during CLP-induced sepsis (N. C. Riedemann, R-F. Guo
et al., manuscript submitted).
Another in vitro study found that C5a strongly reduced
mediator (LPS, interferon-)-induced production of IL-12 in
human monocytes [36]. We recently presented evidence that
LPS-induced TNF- production was significantly reduced in
neutrophils in the copresence of C5a, and the opposite effect
(increased TNF- production) could be seen in macrophages
[27]. We interpret these findings to suggest that C5a inhibits
the production of an important proinflammatory mediator in
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neutrophils, reflecting evidence for a harmful inhibition of
innate-immune functions.
In conclusion, C5a, in most of the in vitro experiments,
seems to significantly enhance mediator-induced production of
cytokines and chemokines with the exception of IL-12 in
PBMC and TNF- in PMN. In the context of sepsis, we believe
that a boost of proinflammatory mediator production early
during the onset of sepsis may explain the significant contri-
bution of C5a in the onset of sepsis (Fig. 1). For specific cell
types (e.g., neutrophils), contact with C5a may result in harm-
ful reduction of certain immune functions, as pointed out below
and in Figure 1.
EVIDENCE FOR HARMFUL EFFECTS OF C5a
ON NEUTROPHIL INNATE IMMUNITY
As pointed out in the paragraphs above, neutrophils seem to
play a special role in the context of C5a effects during sepsis.
IL-6 or LPS does not regulate C5aR in PMN on the transcrip-
tional level, and the surface content on PMN of C5aR has been
demonstrated to decrease during sepsis, and an increase was
observed of C5aR in lungs, liver, kidney, and heart. Upon
contact with C5a, LPS-induced TNF- production appears to
be significantly inhibited by C5a in PMN, and the opposite
effect could be observed in macrophages [27].
C5a has been shown to provoke a transient leukocytosis after
injection into rabbits [37], supporting the concept that C5a
plays an important role for innate immunity via neutrophil
recruitment. An earlier study had suggested that exposure of
high levels of C5a could lead to nonspecific, chemotactic
“deactivation,” thereby causing broad neutrophil dysfunction
[38]. Our group recently found that blood neutrophils from CLP
rats show reduced phagocytosis and defective assembly of
reduced nicotinamide adenine dinucleotide phosphate oxidase
[39]. Blockade of C5a during sepsis prevented these effects,
suggesting a harmful role of C5a for neutrophil innate-immune
functions during sepsis. We have also demonstrated that the
chemotactic ability in neutrophils was compromised during
sepsis as a result of generation of C5a [20]. Recent work
extended these findings by demonstrating that the production
of ROS in neutrophils is compromised during CLP-induced
sepsis in rats related to C5a generation (R-F. Guo, N. C.
Riedemann et al., submitted).
A recent study suggested that C5a was also involved in
altered neutrophil trafficking during sepsis, as a result of
differential regulation of 1-integrins [40].
Fig. 1. The key role of C5a/C5aR activation for the development of sepsis. Depicted are the proinflammatory and immunosuppressive effects of C5a in the context
of sepsis. Rapid complement activation after, e.g., bacterial infection will lead to massive C5a generation at the onset of sepsis, resulting in an overwhelming,
proinflammatory response, including production of proinflammatory mediators such as IL-6, which in turn, enhances C5aR expression in various cell types of solid
organs, increasing the sensitivity to C5a effects. C5a also enhances vascular permeability, contributing to development of edema, resulting in reduced organ
perfusion and oxygen supply. Procoagulatory effects of C5a may promote the development of disseminated intravascular coagulopathy with resulting micro
embolisms in various organs. Proinflammatory mediators as well as C5a lead to a massive production of reactive oxygen species (ROS) in phagocytic cells,
potentially damaging various organs, resulting in multi-organ failure. Conversely, C5a activation results in inhibition of crucial innate-immune functions of
neutrophils, leaving the organism with increased susceptibility to bacterial infection. PMN, Polymorphonuclear leukocytes.
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In conclusion, excessive C5a generation during sepsis ap-
pears to impair crucial innate-immune functions of neutro-
phils, leading to a state of “immune paralysis”, in which the
first line of defense (phagocytosis, H2O2 production) against
invading microorganisms is dysfunctional, leaving the organ-
ism susceptible to bacterial infection or superinfection. Obvi-
ously, C5a appears to have a central role for the regulation of
neutrophil functions during the onset of sepsis. The signaling
pathways involved in these C5a effects are as-yet unknown.
The underlying molecular mechanisms need to be investigated.
OTHER HARMFUL EFFECTS OF C5a DURING
SEPSIS
Besides the impaired innate-immune functions in neutrophils,
other harmful effects of C5a during experimental sepsis have
been described. A recent study demonstrated an eminent role
of C5a for disordered coagulation and fibrinolysis during sepsis
[41]. This study presents the first evidence of a relation be-
tween the complement system and coagulation system in a
setting of experimental sepsis. Disseminated intravascular co-
agulopathy occurs frequently in patients with sepsis and con-
tributes to high mortality rates; such findings are of particular
interest.
Another recently discovered, potentially harmful role of C5a
during sepsis is its ability to induce thymocyte apoptosis under
conditions in which C5aR has been up-regulated [6, 42].
Apoptosis of lymphoid cells during sepsis is thought to be
related to loss of immune functions during sepsis [43, 44]. In
these studies, blockade of C5a during CLP-induced sepsis
resulted in potent inhibition of the otherwise observed and
earlier described rapid thymus involution during sepsis. There-
fore, we hypothesize, that massive C5a generation during the
onset of sepsis could lead to a rapid reduction of immunocytes,
increasing the susceptibility to infection.
SUMMARY
Good complement gone bad? Undoubtedly, recent research
demonstrates that C5a/C5aR play an important role for the
development of sepsis and harmful impairment of crucial in-
nate-immune functions, despite the fact that the complement
system is surely one of the most powerful and important de-
fense mechanisms against invading microorganisms. Based on
our current understanding, we present the hypothesis that in
the context of sepsis, an imbalance of complement activation
may be the underlying phenomenon, resulting in excessive C5a
generation, leading to the conditions outlined above and de-
picted in Figure 1.
The effects elicited by C5a/C5aR interaction appear to be
organ- and cell-type-specific, and much work needs to be done
to define in greater detail the consequences of C5aR activation
for a specific cell type and organ, especially on the molecular
basis. It is fascinating to observe the broad variety of C5a
effects during the onset of sepsis, suggesting C5a to be a key
player for the development of sepsis. C5a/C5aR may be inter-
esting targets, especially for preventive treatment of patients at
high risk for developing sepsis.
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